A P/S near 38x against 45.8% year-over-year revenue growth implies the market is capitalizing a long runway of growth, well above what mid-cap rare disease peers such as RARE, which carry negative multiples, would support on current figures. The P/B of 25.3x reflects a book equity base of roughly $201.5M that is small relative to the market value, so the premium is driven by intangible franchise value rather than tangible assets. Investors should recognize that these multiples are highly sensitive to whether operating margin of -101.2% can narrow toward breakeven, since the valuation case rests on that margin convergence not yet being visible in the reported quarters.

The gross margin profile is consistent with orphan-drug pricing power, but it does not by itself indicate earning power because the cost base sits well above gross profit in most periods. The improvement in operating margin from -143.7% in Q1 2025 to -42.6% in Q3 2026 suggests operating leverage is emerging, though it remains unproven as a durable trend. Net margin of -44.9% tracks operating margin closely, which suggests the loss is operationally driven rather than caused by financing or one-time items.

Minimal total debt of $3.5M against equity of $201.5M means leverage is not the primary balance sheet pressure, and the negative interest coverage primarily reflects operating losses rather than a heavy interest burden. The more relevant constraint is liquidity: cash of $40.0M against a quarterly net loss near $41.4M implies a runway measured in quarters rather than years without new capital. Investors should monitor the timing of equity or partnership financing, since dilution risk appears more material than debt covenant risk.

The headline current ratio and quick ratio remain well above one, but the trend downward over ten quarters suggests that current assets are being consumed by operating losses faster than they are replenished. Because the quick ratio excludes inventory, its strength depends on receivables and cash, and with cash at roughly 9% of total assets, the liquid cushion may be thinner than the ratios imply. Under a severe stress scenario such as a delay in payer coverage, the current ratio could compress further, warranting close monitoring of the next financing event.